Ginkgo Bioworks Q1 revenue $81M, down 52% YoY; Cell Engineering rev up 59%

Ginkgo Bioworks Holdings, Inc.

2023-Q1 EPS reported -$0.11 revenue$80,702,000

Q1 2023 total revenue $81M (down 52% YoY); Cell Engineering rev $34M (+59% YoY); Biosecurity rev $47M (52% gross margin).
Operating loss $(216)M (incl. $75M SBC); Adj. EBITDA $(100)M vs $(1)M prior year. Cash ~$1.2B.
Added 13 new Cell Programs (18% YoY growth); FY2023 outlook: at least 100 new programs, total rev ≥$275M.
Acquired StrideBio's AAV capsid engineering platform to advance gene therapy capabilities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ginkgo Bioworks Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $81 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $81 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity business unit

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020490

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.